Do shared mechanisms underlying cell cycle regulation and synaptic plasticity underlie the reduced incidence of cancer in schizophrenia?

Schizophrenia Research

Volumn 130, Issue 1-3, 2011, Pages 282-284

  Wang, Yang ^a   He, Guang ^a,c   He, Lin ^a,b,c   McGrath, John ^d,e  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^d QUEENSLAND CENTRE FOR MENTAL HEALTH RESEARCH   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cancer; Cell cycle regulation; Genetic factors; Schizophrenia; Synaptic plasticity

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; CANCER INCIDENCE; CANCER RISK; CELL CYCLE REGULATION; DISEASE ASSOCIATION; DRUG EFFECT; HEREDITY; HUMAN; LUNG CANCER; NERVE CELL PLASTICITY; PATHOGENESIS; PRIORITY JOURNAL; PROTECTION; RISK FACTOR; RISK REDUCTION; SCHIZOPHRENIA;

CELL CYCLE; HUMANS; INCIDENCE; NEOPLASMS; NEURONAL PLASTICITY; NEURONS; SCHIZOPHRENIA; SYNAPSES;

EID: 79960293835     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.05.009     Document Type: Article

References (37)

1. Bush C.J., Hodgson R. Schizophrenia and cancer: in 2010 do we understand the connection?. Can. J. Psychiatry 2010, 55(12):761-767.
2. Bushe C.J., Bradley A.J., Wildgust H.J., Hodgson R.E. Schizophrenia and breast cancer incidence: a systematic review of clinical studies. Schizophr. Res. 2009, 114(1-3):6-16.
3. Catts V.S., Catts S.V. Apoptosis and schizophrenia: is the tumour suppressor gene, p53, a candidate susceptibility gene?. Schizophr. Res. 2000, 41(3):405-415.
4. Catts V.S., Catts S.V., O'Toole B.I., Frost A.D. Cancer incidence in patients with schizophrenia and their first-degree relatives - a meta-analysis. Acta Psychiatr. Scand. 2008, 117(5):323-336.
5. Clevers H. Wnt breakers in colon cancer. Cancer Cell 2004, 5(1):5-6.
6. De Ferrari G.V., Moon R.T. The ups and downs of Wnt signaling in prevalent neurological disorders. Oncogene 2006, 25(57):7545-7553.
7. Fanous A.H., Kendler K.S. Genetic heterogeneity, modifier genes, and quantitative phenotypes in psychiatric illness: searching for a framework. Mol. Psychiatry 2005, 10(1):6-13.
8. Feron F., Perry C., Hirning M.H., McGrath J., Mackay-Sim A. Altered adhesion, proliferation and death in neural cultures from adults with schizophrenia. Schizophr. Res. 1999, 40(3):211-218.
9. Frank C.L., Tsai L.H. Alternative functions of core cell cycle regulators in neuronal migration, neuronal maturation, and synaptic plasticity. Neuron 2009, 62(3):312-326.
10. Hippisley-Cox J., Vinogradova Y., Coupland C., Parker C. Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study. Arch. Gen. Psychiatry 2007, 64(12):1368-1376.
11. Hodgson R., Wildgust H.J., Bushe C.J. Cancer and schizophrenia: is there a paradox?. J. Psychopharmacol. 2010, 24(4):51-60.
12. Huang Y.S., Jung M.Y., Sarkissian M., Richter J.D. N-methyl-D-aspartate receptor signaling results in Aurora kinase-catalyzed CPEB phosphorylation and alpha CaMKII mRNA polyadenylation at synapses. EMBO J. 2002, 21(9):2139-2148.
13. Kalkman H.O. The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia. Pharmacol. Ther. 2006, 110(1):117-134.
14. Kalkman H.O. Altered growth factor signaling pathways as the basis of aberrant stem cell maturation in schizophrenia. Pharmacol. Ther. 2009, 121(1):115-122.
15. Kanakry C.G., Li Z., Nakai Y., Sei Y., Weinberger D.R. Neuregulin-1 regulates cell adhesion via an ErbB2/phosphoinositide-3 kinase/Akt-dependent pathway: potential implications for schizophrenia and cancer. PLoS ONE 2007, 2(12):e1369.
16. Kim A.H., Puram S.V., Bilimoria P.M., Ikeuchi Y., Keough S., Wong M., Rowitch D., Bonni A. A centrosomal Cdc20-APC pathway controls dendrite morphogenesis in postmitotic neurons. Cell 2009, 136(2):322-336.
17. Lasky J.L., Wu H. Notch signaling, brain development, and human disease. Pediatr. Res. 2005, 57(5 Pt 2):104R-109R.
18. Lasorella A., Stegmuller J., Guardavaccaro D., Liu G., Carro M.S., Rothschild G., de la Torre-Ubieta L., Pagano M., Bonni A., Iavarone A. Degradation of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal growth. Nature 2006, 442(7101):471-474.
19. Leucht S., Burkard T., Henderson J., Maj M., Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr. Scand. 2007, 116(5):317-333.
20. Lichtermann D., Ekelund J., Pukkala E., Tanskanen A., Lonnqvist J. Incidence of cancer among persons with schizophrenia and their relatives. Arch. Gen. Psychiatry 2001, 58(6):573-578.
21. Matigian N., Abrahamsen G., Sutharsan R., Cook A.L., Vitale A.M., Nouwens A., Bellette B., An J., Anderson M., Beckhouse A.G., et al. Disease-specific, neurosphere-derived cells as models for brain disorders. Dis. Model. Mech. 2010, 3(11-12):785-798.
22. McConnell S.K. The determination of neuronal fate in the cerebral cortex. TINS 1989, 12(9):342-349.
23. McConnell S.K., Kaznowski C.E. Cell cycle dependence of laminar determination in developing neocortex. Science 1991, 254(5029):282-285.
24. McCurdy R.D., Feron F., Perry C., Chant D.C., McLean D., Matigian N., Hayward N.K., McGrath J.J., Mackay-Sim A. Cell cycle alterations in biopsied olfactory neuroepithelium in schizophrenia and bipolar I disorder using cell culture and gene expression analyses. Schizophr. Res. 2006, 82(2-3):163-173.
25. McGrath J.J. The surprisingly rich contours of schizophrenia epidemiology. Arch. Gen. Psychiatry 2007, 64(1):14-16.
26. McGrath J.J., Richards L.J. Why schizophrenia epidemiology needs neurobiology-and vice versa. Schizophr. Bull. 2009, 35(3):577-581.
27. Mei L., Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat. Rev. Neurosci. 2008, 9(6):437-452.
28. Montero J.C., Rodriguez-Barrueco R., Ocana A., Diaz-Rodriguez E., Esparis-Ogando A., Pandiella A. Neuregulins and cancer. Clin. Cancer Res. 2008, 14(11):3237-3241.
29. Numata S., Ueno S., Iga J., Yamauchi K., Hongwei S., Hashimoto R., Takeda M., Kunugi H., Itakura M., Ohmori T. TGFBR2 gene expression and genetic association with schizophrenia. J. Psychiatr. Res. 2008, 42(6):425-432.
30. Park J.K., Lee H.J., Kim J.W., Park Y.H., Lee S.S., Chang H.I., Song J.Y., Yoon D.J., Bahn G.H., Shin Y.H., et al. Differences in p53 gene polymorphisms between Korean schizophrenia and lung cancer patients. Schizophr. Res. 2004, 67(1):71-74.
31. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch. Gen. Psychiatry 2007, 64(10):1123-1131.
32. Sale E.M., Sale G.J. Protein kinase B: signalling roles and therapeutic targeting. Cell. Mol. Life Sci. 2008, 65(1):113-127.
33. Tamminga C.A., Holcomb H.H. Phenotype of schizophrenia: a review and formulation. Mol. Psychiatry 2005, 10(1):27-39.
34. Tran E., Rouillon F., Loze J.Y., Casadebaig F., Philippe A., Vitry F., Limosin F. Cancer mortality in patients with schizophrenia: an 11-year prospective cohort study. Cancer 2009, 115(15):3555-3562.
35. Wang Y., Wang L., Li X., Liu B., Zhao Q., Chen P., Wang T., Li T., Ji J., Yang F., et al. Polymorphisms of XRCC4 are involved in reduced colorectal cancer risk in Chinese schizophrenia patients. BMC Cancer 2010, 10:523.
36. Wray N.R., Visscher P.M. Narrowing the boundaries of the genetic architecture of schizophrenia. Schizophr. Bull. 2010, 36(1):14-23.
37. Xu Y., Pasche B. TGF-beta signaling alterations and susceptibility to colorectal cancer. Hum. Mol. Genet. 2007, 16(Spec No 1):R14-R20.